1. Home
  2. BAND vs MLYS Comparison

BAND vs MLYS Comparison

Compare BAND & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAND
  • MLYS
  • Stock Information
  • Founded
  • BAND 2000
  • MLYS 2019
  • Country
  • BAND United States
  • MLYS United States
  • Employees
  • BAND N/A
  • MLYS N/A
  • Industry
  • BAND Computer Software: Prepackaged Software
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BAND Technology
  • MLYS Health Care
  • Exchange
  • BAND Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • BAND 495.2M
  • MLYS 510.6M
  • IPO Year
  • BAND 2017
  • MLYS 2023
  • Fundamental
  • Price
  • BAND $17.00
  • MLYS $9.56
  • Analyst Decision
  • BAND Buy
  • MLYS Strong Buy
  • Analyst Count
  • BAND 8
  • MLYS 2
  • Target Price
  • BAND $27.43
  • MLYS $27.00
  • AVG Volume (30 Days)
  • BAND 341.3K
  • MLYS 280.6K
  • Earning Date
  • BAND 02-20-2025
  • MLYS 02-12-2025
  • Dividend Yield
  • BAND N/A
  • MLYS N/A
  • EPS Growth
  • BAND N/A
  • MLYS N/A
  • EPS
  • BAND N/A
  • MLYS N/A
  • Revenue
  • BAND $748,487,000.00
  • MLYS N/A
  • Revenue This Year
  • BAND $25.91
  • MLYS N/A
  • Revenue Next Year
  • BAND $3.05
  • MLYS N/A
  • P/E Ratio
  • BAND N/A
  • MLYS N/A
  • Revenue Growth
  • BAND 24.52
  • MLYS N/A
  • 52 Week Low
  • BAND $11.90
  • MLYS $8.58
  • 52 Week High
  • BAND $25.02
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • BAND 42.02
  • MLYS 42.42
  • Support Level
  • BAND $15.80
  • MLYS $8.98
  • Resistance Level
  • BAND $19.88
  • MLYS $10.75
  • Average True Range (ATR)
  • BAND 0.89
  • MLYS 0.72
  • MACD
  • BAND -0.10
  • MLYS 0.02
  • Stochastic Oscillator
  • BAND 29.41
  • MLYS 27.49

About BAND Bandwidth Inc.

Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to large as well as small and medium-sized business, customers and is generally derived from usage and service fees. Usage revenue includes voice communication (driven by inbound and outbound minutes and toll-free minutes) and messaging communication (driven by the number of messages) that traverse the platform and network. Service fees include the provision and management of phone numbers and emergency services access.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: